ReShape Lifesciences Shareholders Approve Merger with Vyome Therapeutics, Effective August 15, 2025

Reuters08-08
<a href="https://laohu8.com/S/RSLS">ReShape Lifesciences</a> Shareholders Approve Merger with Vyome <a href="https://laohu8.com/S/LENZ">Therapeutics</a>, Effective August 15, 2025

ReShape Lifesciences Inc. has announced that its shareholders have approved all necessary proposals for the merger with Vyome Therapeutics. The merger is expected to become effective on August 15, 2025, aligning with the commencement of trading of the combined company's shares under the new name Vyome Holdings, Inc. on The Nasdaq Capital Market, with the trading symbol "HIND". The merger emphasizes Vyome's aim to establish a healthcare platform across the US-India innovation corridor. Both companies are supported by financial advisors and legal counsel, indicating a coordinated effort to ensure a smooth transition.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250807164498) on August 07, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment